Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)

被引：4

作者：

Stein, Alexander

Binder, Mascha

Goekkurt, Eray

Lorenzen, Sylvie

Riera-Knorrenschild, Jorge

Depenbusch, Reinhard

Ettrich, Thomas Jens

Doerfel, Steffen

Al-Batran, Salah-Eddin

Karthaus, Meinolf

Pelzer, Uwe

Simnica, Donjete

Waberer, Lisa

Hinke, Axel

Bokemeyer, Carsten

Hegewisch-Becker, Susanna

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Haematol Stem Cell Transplantat & Pneu, Hamburg, Germany

[2] Univ Med Ctr Halle Saale, Dept Internal Med 4, Halle, Germany

[3] Hematol Oncol Practice Eppendorf, Hamburg, Germany

[4] Univ Canc Ctr Hamburg, Hamburg, Germany

[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med Hematol Med Oncol 3, Munich, Germany

[6] Univ Klin Marburg, Marburg, Germany

[7] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany

[8] Ulm Univ Hosp, Ulm, Germany

[9] Onkozentrum Dresden, Dresden, Germany

[10] UCT Univ Canc Ctr, Krankenhaus Nordwest, Inst Clin Res IKF, Frankfurt, Germany

[11] Klinikum Neuperlach, Munich, Germany

[12] Charite, Berlin, Germany

[13] Univ Halle, Halle, Germany

[14] IKF GmbH Krankenhaus Nordwest, Frankfurt, Germany

[15] CCRC Canc Clin Res Consulting, Dusseldorf, Germany

[16] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[17] HOPE Hamatol Onkol Praxis Eppendorf, Hamburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
Binder, Mascha
Goekkurt, Eray
Lorenzen, Sylvie
Riera-Knorrenschild, Jorge
Depenbusch, Reinhard
Ettrich, Thomas
Doerfel, Steffen
Al-Batran, Salah
Karthaus, Meinolf
Pelzer, Uwe
Simnica, Donjete
Waberer, Lisa
Hinke, Axel
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
Tintelnot, Joseph
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
Stein, Alexander
Binder, Mascha
Al-Batran, Salah-Eddin
Hinke, Axel
Waberer, Lisa
Goekkurt, Eray
Meyer, Tobias
Statovci, Donjete
Depenbusch, Reinhard
Riera-Knorrenschild, Jorge
Lorenzen, Sylvie
Ettrich, Thomas Jens
Doerfel, Steffen
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): The phase II AVETUX-CRC trial (AIO KRK 0216).
Stein, Alexander
Binder, Mascha
Bokemeyer, Carsten
Al Batran, Salah Eddin
Hinke, Axel
Hegewisch-Becker, Susanna
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Tintelnot, Joseph
Ristow, Inka
Sauer, Markus
Simnica, Donjete
Schultheiss, Christoph
Scholz, Rebekka
Goekkurt, Eray
von Wenserski, Lisa
Willscher, Edith
Paschold, Lisa
Lorenzen, Sylvie
Riera-Knorrenschild, Jorge
Depenbusch, Reinhard
Ettrich, Thomas J.
Doerfel, Steffen
Al-Batran, Salah-Eddin
Karthaus, Meinolf
Pelzer, Uwe
Hinke, Axel
Bauer, Marcus
Massa, Chiara
Seliger, Barbara
Wickenhauser, Claudia
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
Binder, Mascha
Stein, Alexander
FRONTIERS IN ONCOLOGY, 2022, 12
[5] FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
Samalin, E.
Desseigne, F.
Thezenas, S.
Bibeau, F.
Viret, F.
Mineur, L.
Assenat, E.
Bleuse, J.
Portales, F.
Crapez, E.
Ychou, M.
ANNALS OF ONCOLOGY, 2009, 20 : 20 - 20
[6] Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Stein, Alexander
Kretzschmar, Albrecht
Behringer, Dirk
Wolff, Thomas
Zimber, Joachim
Hegewisch-Becker, Susanna
Kettner, Erika
Pflueger, Karl-Heinz
Kirsch, Andreas
Arnold, Dirk
BMC CANCER, 2013, 13
[7] Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Alexander Stein
Albrecht Kretzschmar
Dirk Behringer
Thomas Wolff
Joachim Zimber
Susanna Hegewisch-Becker
Erika Kettner
Karl-Heinz Pflüger
Andreas Kirsch
Dirk Arnold
BMC Cancer, 13
[8] Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)
Stintzing, S.
Dechow, T. N.
Vehling-Kaiser, U.
Lorenzen, S.
Hannig, C-V.
Schwaner, I.
Von Weikersthal, L. Fischer
Puchtler, G.
Binder, M.
Held, S.
Heinrich, K.
Heinemann, V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S729 - S729
[9] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
Schmoll, Hans-Joachim
Garlipp, Benjamin
Junghanss, Christian
Leithaeuser, Malte
Vogel, Arndt
Schaefers, Michael
Kaiser, Ulrich
Hoeffkes, Heinz-Gert
Florschuetz, Axel
Ruessel, Joern
Kanzler, Stephan
Edelmann, Thomas
Forstbauer, Helmut
Goehler, Thomas
Hannig, Carla
Hildebrandt, Bert
Steighardt, Joerg
Meinert, Fabian Maximilian
Cygon, Franziska
Stein, Alexander
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[10] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
Hoehler, T.
von Wichert, G.
Schimanski, C.
Kanzler, S.
Moehler, M. H.
Hinke, A.
Seufferlein, T.
Siebler, J.
Hochhaus, A.
Arnold, D.
Hallek, M.
Hofheinz, R.
Hacker, U. T.
BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413

← 1 2 3 4 5 →